Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey

The Liver Cancer Study Group Of Japan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. Methods: BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. Results: There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child–Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. Conclusions: Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalJournal of Gastroenterology
DOIs
Publication statusAccepted/In press - 2017 Feb 21

Fingerprint

Hepatocellular Carcinoma
alpha-Fetoproteins
Serology
Survival Rate
Survival
Liver
Surveys and Questionnaires
Bilirubin
Albumins
Serum

Keywords

  • Hepatocellular carcinoma
  • Liver function
  • Prognosis
  • Serological markers
  • Staging
  • Tumor progression

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. / The Liver Cancer Study Group Of Japan.

In: Journal of Gastroenterology, 21.02.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{7afce25429c346788fb57b0b295c90b0,
title = "Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey",
abstract = "Background: Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. Methods: BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. Results: There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child–Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. Conclusions: Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.",
keywords = "Hepatocellular carcinoma, Liver function, Prognosis, Serological markers, Staging, Tumor progression",
author = "{The Liver Cancer Study Group Of Japan} and Hienori Toyoda and Toshifumi Tada and Johnson, {Philip J.} and Namiki Izumi and Masumi Kadoya and Shuichi Kaneko and Norihiro Kokudo and Yonson Ku and Shoji Kubo and Takashi Kumada and Yutaka Matsuyama and Osamu Nakashima and Michiie Sakamoto and Tadatoshi Takayama and Masatoshi Kudo",
year = "2017",
month = "2",
day = "21",
doi = "10.1007/s00535-017-1321-6",
language = "English",
pages = "1--10",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey

AU - The Liver Cancer Study Group Of Japan

AU - Toyoda, Hienori

AU - Tada, Toshifumi

AU - Johnson, Philip J.

AU - Izumi, Namiki

AU - Kadoya, Masumi

AU - Kaneko, Shuichi

AU - Kokudo, Norihiro

AU - Ku, Yonson

AU - Kubo, Shoji

AU - Kumada, Takashi

AU - Matsuyama, Yutaka

AU - Nakashima, Osamu

AU - Sakamoto, Michiie

AU - Takayama, Tadatoshi

AU - Kudo, Masatoshi

PY - 2017/2/21

Y1 - 2017/2/21

N2 - Background: Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. Methods: BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. Results: There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child–Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. Conclusions: Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.

AB - Background: Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. Methods: BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. Results: There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child–Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. Conclusions: Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.

KW - Hepatocellular carcinoma

KW - Liver function

KW - Prognosis

KW - Serological markers

KW - Staging

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85013371949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013371949&partnerID=8YFLogxK

U2 - 10.1007/s00535-017-1321-6

DO - 10.1007/s00535-017-1321-6

M3 - Article

SP - 1

EP - 10

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

ER -